Vaxcyte, Inc. Stock Price, News & Analysis

Vaxcyte announced the dosing of the first participants in the Phase 2 portion of its Phase 1/2 clinical trial for VAX-24, a 24-valent pneumococcal conjugate vaccine. The independent Data Monitoring Committee recommended proceeding after reviewing Phase 1 safety data. Vaxcyte aims to deliver broader protection against invasive pneumococcal disease and pneumonia. Topline results from both trial phases are expected by the end of 2022, highlighting the candidate's potential to improve standard vaccination practices.

Vaxcyte, Inc. (PCVX) announced the initiation of a Phase 1/2 clinical study for its 24-valent pneumococcal conjugate vaccine, VAX-24, aimed at preventing invasive pneumococcal disease in adults. The study's topline safety and immunogenicity results are expected by the end of 2022. The company reported a cash position of $273.1 million as of December 31, 2021, excluding $107.6 million from a recent public offering. Vaxcyte also highlighted increased R&D costs and a net loss of $100.1 million for 2021, signaling ongoing investment in its vaccine pipeline.

Vaxcyte (PCVX) announced the initiation of a Phase 1/2 clinical study for VAX-24, a 24-valent pneumococcal conjugate vaccine. This proof-of-concept study will assess the safety, tolerability, and immunogenicity of VAX-24 in adults, with topline results expected by the end of 2022. The study aims to prevent invasive pneumococcal disease and pneumonia, which significantly affect public health. The vaccine targets emerging serotypes not included in existing vaccines, addressing the significant morbidity and mortality associated with pneumococcal diseases.

Vaxcyte, Inc. (PCVX) will report its fourth quarter and full year 2021 financial results on February 28, 2022, after market close. The management will host a conference call at 4:30 p.m. ET to discuss these results and provide a business update. Vaxcyte is focused on developing innovative vaccines, with its lead candidate being VAX-24, a 24-valent pneumococcal conjugate vaccine aimed at preventing invasive pneumococcal disease. The company utilizes advanced synthetic techniques, including the XpressCF™ platform, to enhance vaccine efficacy and production.

Vaxcyte (Nasdaq: PCVX) announced that management will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022. The presentation is set for 2:20 p.m. ET / 11:20 a.m. PT. A live webcast will be available on the company’s website, with a replay accessible for 30 days post-conference. Vaxcyte focuses on engineering high-fidelity vaccines to combat bacterial diseases, with its lead candidate, VAX-24, aimed at preventing invasive pneumococcal disease.

Vaxcyte, Inc. (Nasdaq: PCVX) has announced a public offering of 2,500,000 shares of common stock and pre-funded warrants, priced at $20.00 and $19.999 per share, respectively. The offering is expected to generate approximately $100 million in gross proceeds, excluding the exercise of warrants. The offering is anticipated to close on January 18, 2022, subject to customary conditions. Vaxcyte has also granted underwriters a 30-day option for an additional 750,000 shares.

Vaxcyte, Inc. (Nasdaq: PCVX) announced a public offering of common stock and pre-funded warrants, with underwriters having a 30-day option to purchase an additional 15% of shares. The offering's terms are subject to market conditions and lack definitive timelines. Leading the offering are BofA Securities, Jefferies, and Evercore ISI. A shelf registration statement has been effective since July 2, 2021. The company's focus is on developing advanced vaccines, including its lead candidate, VAX-24, targeting invasive pneumococcal disease.

Vaxcyte, Inc. (Nasdaq: PCVX) announced the FDA's clearance of the Investigational New Drug application for VAX-24, its 24-valent pneumococcal conjugate vaccine. This marks a pivotal step as Vaxcyte transitions to a clinical-stage company. The Phase 1/2 clinical study is set to initiate in Q1 2022, with topline results expected by the end of the year. VAX-24 aims to address the significant public health challenge of pneumococcal disease, which affects hundreds of thousands annually in the U.S. The company is also advancing VAX-XP, designed to cover over 30 strains.

Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine developer, will participate in several virtual investor conferences aimed at enhancing global health through innovative vaccine solutions. Key events include the Jefferies London Healthcare Conference from November 16-19, 2021, the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29-December 2, 2021, and the Evercore ISI 4th Annual HealthCONx Virtual Conference from November 30-December 2, 2021. Webcasts of these discussions will be available on Vaxcyte’s website for about 30 days.